Ligand Pharmaceuticals Incorporated (LGND) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.

Total Cash From Operating Activities Chart for Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated (LGND) operating cash flow for FY2025 was USD 49.4M, a -49.1% change from FY2024. Ligand Pharmaceuticals Incorporated's operating cash flow moved from USD -14.3M in 1994 to USD 49.4M in 2025 over 31 years. Operating cash flow compound annual growth rate: 5-year CAGR of -2.0%, 10-year CAGR of 1.7%, 20-year CAGR of 9.3%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$6.05B
Implied Share Price
$303.53
Enterprise Value
$5.72B
Revenue (TTM)
$290.54M
EBITDA
$133.01M
Profit Margin
67.88%
Trailing P/E
32.46
Forward P/E
24.81
Price/Book (MRQ)
6.16
Price/Sales (TTM)
20.83
EV/EBITDA
20.64
EV/Revenue
19.68
Dividend Yield
—
Book Value
$48.57
Free Cash Flow (FY2025)
$48.91M
Free Cash Flow Yield
0.81%

Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.